Enterprise Value

17.2M

Cash

58.04M

Avg Qtr Burn

-8.778M

Short % of Float

2.49%

Insider Ownership

2.68%

Institutional Own.

58.25%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Uproleselan (GMI-1271) Details
Acute myeloid leukemia, Cancer

Phase 3

Data readout

Phase 2/3

Data readout

Phase 1/2

Data readout

Phase 1/2

Data readout

GMI-1687 Details
Sickle cell disease

Phase 1a

Data readout

Rivipansel (GMI-1070) Details
SCD (Sickle Cell Disease)

Failed

Discontinued

GMI-1359 Details
Breast cancer

Failed

Discontinued